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Abstract
Arrhythmias are common after cardiac surgery such as coronary artery bypass grafting 
surgery. Although most of these arrhythmias are transient and have a benign course, it 
may represent a significant source of morbidity and mortality. Postoperative arrhyth-
mias (POAs) include atrial tachyarrhythmias, ventricular arrhythmias, and bradyar-
rhythmias. The incidence of POAs has not changed despite improvements in anesthetic 
and surgical techniques. The tachyarrhythmias in the postoperative period include atrial 
fibrillation, atrial flutter, supraventricular tachycardia, and ventricular tachycardia. The 
clinical significance of each arrhythmia depends on several factors that include cardiac 
function, patient’s comorbidities, arrhythmia duration, and ventricular response rate. 
Tachycardia with uncontrolled ventricular rates can cause diastolic and later on systolic 
dysfunction, reduce cardiac output, and result in hypotension or myocardial ischemia. 
In the other hand, bradyarrhythmias may have a remarkable influence on patients with 
systolic or diastolic ventricular dysfunction. Arrhythmia management starts preopera-
tively with optimizing the patient’s condition and controlling patient’s risk factors, intra-
operatively with careful attention to hemodynamic changes during surgery and uses 
appropriate anesthesia, and postoperatively with correction of temporary and correct-
able predisposing factors, as well as specific therapy for the arrhythmia itself. The POAs 
treatment urgency and management options are determined by the clinical presentation 
of the arrhythmia.
Keywords: coronary artery bypass surgery, arrhythmias, atrial fibrillation, ventricular 
arrhythmias, bradyarrhythmias
1. Introduction
Arrhythmias are common after cardiac surgery such as coronary artery bypass grafting 
(CABG) surgery and represent a significant source of morbidity and mortality. Although most 
of these arrhythmias are transient and have a benign course, it may prolong intensive care 
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and hospital stay, and in rare instances, it may lead to mortality. Postoperative arrhythmias 
(POAs) include atrial tachyarrhythmias (ATs) and to a lesser extent ventricular arrhythmias 
(VAs) and bradyarrhythmias [1]. The incidence of POAs has not changed despite improve-
ments in anesthetic and surgical techniques, and evidence suggests that its incidence may be 
increasing [2].
The clinical significance of each arrhythmia depends on several factors that include underly-
ing cardiac function, patient’s comorbidities, arrhythmia duration, and ventricular response 
rate. So, POAs could be tolerated in some patients and a source of morbidity and mortality in 
others, depending on the interaction between these factors [1, 3]. Rapid ventricular rates with 
tachycardia can cause diastolic and later on systolic dysfunction, reduce cardiac output, and 
result in hypotension or myocardial ischemia [4, 5]. Bradydysrhythmias, particularly with the 
loss of atrial function, may have a remarkable influence on patients with systolic or diastolic 
ventricular dysfunction [6].
Arrhythmia management starts preoperatively with optimization of the patient’s condi-
tion and controlling patient’s risk factors. Intraoperatively, it includes careful attention to 
hemodynamic changes during surgery and uses appropriate anesthesia. Postoperatively, it 
includes correction of temporary and correctable predisposing factors, as well as specific 
therapy for the arrhythmia itself [7]. The POAs treatment urgency and management options 
are determined by the clinical presentation of the arrhythmia [7]. Self-terminating arrhyth-
mias without overt cardiac disease often need no therapy. However, arrhythmias with 
hemodynamic instability, especially in patients with critical stress conditions like systemic 
infections or persistent pericardial effusion need urgent intervention to restore a stable clini-
cal status [7].
The aim of this chapter is to review post-CABG arrhythmias pathophysiology and management.
2. Pathophysiology
The primary function of CABG is to reestablish perfusion to ischemic myocardium with uti-
lizing autologous arteries and veins. This may be achieved by using different surgical tech-
niques. The POAs pathophysiology, incidence, and clinical course may vary depending on 
the surgical techniques used. Initially, cardiac surgeries were performed on a beating heart, 
but with the development of cardiopulmonary bypass (CPB) machine and cardioplegia, most 
CABG surgeries were performed on a pump. However, interest in off-pump coronary artery 
bypass (OPCAB) surgery had revived in the 1990s [8]. Reported potential benefits of OPCAB 
include lower end-organ damage with less cerebrovascular accidents (CVA), fewer cognitive 
deficits, renal failure, less psychomotor defects, reduced systemic inflammation, and lower 
transfusion rates [9]. However, variable outcomes have been reported in studies comparing 
these strategies [9]. Minimally invasive surgery without use of CPB and through smaller inci-
sions- and robotic-assisted approaches have also been developed [9]. This method is most 
often used for left internal mammary artery (LIMA) to left anterior descending artery (LAD) 
grafts. Additional benefits may also include reduced operative time, reduced recovery time, 
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decreased the need for blood transfusion, less time under anesthesia, reduced duration of ICU 
stay, less pain, and an estimated 40% savings over conventional CABG [10].
The development of POAs is related to factors that influence the atrial and ventricular myocar-
dium. These primarily include: a previous anatomic substrate, caused by degenerative changes 
typical of age and underlying disease, and electrical substrate derived from the perioperative 
processes that alter the membrane potentials, increase the dispersion of the refractory peri-
ods, and decrease the conduction velocity [11]. Inflammation and hyperadrenergic state appear 
to play a fundamental role in the development of postoperative tachyarrhythmias, favoring 
automatism [11]. Hypokalemia and hypomagnesemia characteristic of this period alter phase 
III of the membrane action potential, increasing the automatism, and slowing the conduction 
speed [11]. Atrial and ventricular ischemia due to hypoxemia is another contributing factor [11].
Several perioperative risk factors have been implicated in atrial and ventricular susceptibility 
to POAs, but their relative role is still uncertain. Risk factors for POAs may be classified into 
patient- and surgery-related factors [7].
2.1. Patient-related risk factors
Various patient-related risk factors have been described to cause POAs. These include:
2.1.1. Age
Increasing age is associated with age-related structural and electrophysiological changes that 
may lead to postoperative atrial tachyarrhythmias in the elderly. Old age has been demon-
strated to be correlated with the development of POAs [2, 3, 12–14].
2.1.2. Underlying structural heart disease
Patients with underlying structural heart disease are at higher risk of developing POAs com-
pared to patients with a normal heart. Structural heart disease in the atria and ventricles provides 
a substrate for arrhythmia via abnormal automaticity, triggered activity, or reentry. Cardiac sur-
gery patients often have the substrate of atrial enlargement and elevation of atrial pressures may 
function as a substrate for atrial arrhythmias. It is well known that large atrial size and fibrosis 
supports propagation of atrial reentrant circuits and helps in maintaining atrial fibrillation (AF). 
Similarly, patients with ventricular dysfunction, ventricular dilation, or fibrosis are at higher risk 
of having ventricular arrhythmias [4]. Other important risk factors for POAs include previous 
history of arrhythmias (e.g., AF), cardiac surgery, and POAs. Also, severe right coronary artery 
stenosis [15], sinus nodal or atrioventricular nodal branch disease [13, 16, 17], and mitral valvular 
disease (particularly rheumatic mitral stenosis) have been reported as risk factors for POAs. The 
preoperative brain natriuretic peptide plasma concentration is another predictor of POAs [18].
2.1.3. Other comorbidities
Noncardiac comorbidities have been reported to increase the risk of POAs especially AF. These 
include obesity [19], previous stroke, and history of chronic obstructive pulmonary disease [20].
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2.2. Surgery-related risk factors
Cardiac surgery may lead to POAs via multiple surgery-related mechanisms and risk factors 
that include:
2.2.1. Trauma and inflammation
Cardiac surgery provokes a vigorous inflammatory response due to a variety of metabolic, 
endocrine, and immune changes known as the “stress response,” which has important clini-
cal implications [21, 22] (Figure 1). Surgical trauma, blood loss or transfusion, hypothermia, 
and CPB are nonspecific activators of the inflammatory response [18, 19]. Surgical trauma 
may contribute to a higher degree of the inflammatory response compared to CPB [23]. These 
effects predispose to atrial and ventricular arrhythmias in the early postoperative period. 
Inflammatory mechanisms have been proposed for the development of postoperative AF 
(POAF) as its incidence peaks at early postoperative days. Inflammation may be related to 
the development of clinically aberrant or silent pericarditis. Unfortunately, clinical criteria, 
such as fever, pleuritic chest pain, pericardial rubs, and electrocardiogram changes corre-
late poorly with postoperative pericarditis and supraventricular arrhythmias [7]. However, 
patients with pericardial effusion in one study had a higher incidence of supraventricular 
arrhythmias (63% compared with 11% in patients without effusions) [24].
Figure 1. Pathophysiologic changes in response to cardiopulmonary bypass and the extracorporeal circulation. ROS, 
reactive oxygen species; SIRS, systemic inflammatory response syndrome (from Ref. [22]).
Coronary Artery Bypass Graft Surgery110
2.2.2. Hemodynamic stress
Atrial and ventricular hemodynamic changes during CABG predispose to POAs. The risk fac-
tors for POAs include atrial changes at the time of cardiac surgery, such as acute atrial trauma 
from cannulation, enlargement, hypertension, and ischemia [7]. Postoperative pulmonary 
edema and postoperative pleural effusion requiring thoracentesis have also been described 
as possible risk factors [25]. Hemodynamic changes might trigger focal arrhythmias [7]. It is 
possible that atrial stretch, hypertension, pressure and volume shifts, and heightened cat-
echolamine states can trigger AF foci from the pulmonary veins [26].
2.2.3. Ischemic injury
The coronary blood flow is interrupted during CABG surgery and CPB, and the heart is put 
under circulatory arrest. This interruption of coronary blood flow causes ischemia-reperfu-
sion injury that is exacerbated by adverse neutrophil-mediated myocardial inflammation and 
injury [27–29]. Atrial and ventricular ischemia or infarction triggers POAs [30]. Myocardial 
focal ischemia may occur due to endogenous or exogenous catecholamines, hypoxemia, 
hypercarbia, acid-base imbalances, drug effects, and mechanical factors. CPB, cross-clamp 
times, type of cardioplegia, and CABG surgical technique are also critical in determining isch-
emic injury. The incidence of AF has been demonstrated to be lower after OPCAB than con-
ventional CABG. OPCAB is also associated with a lesser degree of inflammation [21].
2.2.4. Perioperative drugs
Beta-blocker withdrawal has been associated with an increased rate of postoperative supra-
ventricular arrhythmias [31]. In contrary, some studies showed that preoperative digoxin use 
is a risk factor for POAs [2, 32], but not in the others [33]. Intravenous inotropic agents may 
be associated with POAs in some patients. The reported primary arrhythmias are sinus tachy-
cardia (ST) and premature ventricular beats (PVCs), although other supraventricular (SVT) or 
ventricular arrhythmias (VT) have been reported. Clinically significant proarrhythmic effects 
with these agents appear to occur rarely. At conventional doses, intravenous inotropic agents 
are relatively safe concerning proarrhythmic effects. Inotropic agents increase sinoatrial node 
automaticity and decrease atrioventricular (AV) nodal conduction time [34, 35]. Dobutamine 
use has been reported to induce ventricular ectopic activity in 3–15% of patients [34]. Dopamine 
is more likely to be associated with a dose-related ST or AF [34]. Finally, short-term intrave-
nous administration of the phosphodiesterase inhibitors amrinone and milrinone has been 
reported to cause PVCs and short runs of VT in up to 17% of patients [34]. Amiodarone and 
sotalol are useful and can be considered appropriate alternatives in high-risk patients [36]. 
Patients who need urgent CABG may benefit from intravenous and oral amiodarone combina-
tion in addition to beta-blockers. Although corticosteroids are associated with risk, it may be 
considered in selected CABG patients [36].
2.2.5. Electrolytes disorders
Hypokalemia leads to alteration of the electrophysiologic properties of cardiac myocytes with 
an increase in the action potential duration (increase in phase-3 depolarization), enhanced 
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automaticity (increased slope of diastolic depolarization), and decreased conduction veloc-
ity [37]. These changes may provoke POAs [37]. Preoperative serum potassium levels of 
<3.5 mmol/L have a significant association with perioperative arrhythmias in patients under-
going elective CABG surgery [37].This association might be particularly evident in the atria, 
where changes in inward-rectifier potassium currents are supposed to act as profibrilla-
tory mechanisms [38]. However, hypokalemia is more likely to be associated with VAs [38]. 
Moreover, it is worth noting that arrhythmogenesis is often multifactorial. Catecholamine 
release increases cellular potassium uptake and thus decreases serum potassium levels [39]. 
Serum potassium levels greater than 5.5 mmol/L appear to be associated with the develop-
ment of POAF and atrial flutter (AFL) [37]. The role of magnesium remains controversial. The 
low serum magnesium levels—which is frequently seen after cardiac surgery—correlate with 
an increased incidence of POAs [7]. However, magnesium supplementation has produced 
conflicting results. Magnesium supplementation should be considered in all patients with 
hypomagnesemia [40–41].
2.2.6. Other factors
The human epicardial fat pads (FPs) contain parasympathetic ganglia [42]. There are two 
posterior FPs with the first one located in the superior vena caval-atrial junction and con-
tains postganglionic fibers that lead to the sinoatrial (SA) node. The second FP is located 
at the pulmonary vein-left atrium and contains postganglionic fibers that lead to the atrio-
ventricular (AV) node [43–45]. The anterior epicardial FP located in the aortopulmonary 
window that is routinely dissected and removed in CABG because it is located where the 
aortic cross-clamp is typically placed. Preservation of the human anterior epicardial FP dur-
ing CABG decreases the incidence of POAF in one study [46], but not in another more recent 
study [47].
3. Postoperative atrial tachyarrhythmias (POATs)
3.1. Postoperative atrial fibrillation (POAF)
3.1.1. Epidemiology
AF is the most common complication seen after CABG surgery. The incidence of POAF is 
approximately 30% after isolated CABG, 40% after valve replacements or repair, and about 
50% after combined CABG and valve surgeries [2, 48–51]. The incidence of POAF increases 
with older age [2, 52, 53].
3.1.2. Diagnosis
The diagnosis of POAF is confirmed based on the telemetry and 12-lead electrocardiogram 
(ECG) recordings with an abrupt change in heart rate and rhythm, and loss of P waves [16, 54]. 
Atrial electrograms obtained from temporary atrial epicardial pacing wires that are often rou-
tinely placed at the time of cardiac surgery can be helpful in confirming the diagnosis of AF, AFL, 
and other forms of supraventricular tachycardia (SVTs) [54].
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3.1.3. Clinical course
POAF usually occurs within 2–4 days after cardiac surgery, with a peak incidence on the sec-
ond postoperative day [12, 55]. In POAF patients without a prior history of atrial arrhythmias, 
AF is usually self-limited. About 15–30% of POAF convert to sinus rhythm within 2 h and up 
to 80% within 24 h [56, 57]. The mean duration of AF in one report was 11–12 h [57], and >90% 
of the patients were in sinus rhythm 6–8 weeks after surgery [57, 58]. In another study, only 2 
out of 112 patients who had paroxysmal AF after CABG were still in AF at 6 weeks [59].
3.1.4. Prognosis
Although POAF is often self-limiting, its clinical effects depend on ventricular rate, ventricular 
function, arrhythmia duration, symptoms, hemodynamic stability, and risk of thromboembolism. 
[60]. POAF is associated with increased postoperative thromboembolic risk and stroke [25, 60–62]. 
In a series of 4507 patients, the incidence of stroke was significantly higher in those who devel-
oped POAF (3.3 versus 1.4%) [2]. Patient’s underlying comorbidities, such as older age, previ-
ous cerebrovascular disease (CVA), the presence of a carotid bruit, peripheral vascular disease 
(PVD), and CPB time, have an important role in the development of in-hospital stroke [63–65]. 
In a review of 2972 patients undergoing CABG and/or valve surgery, POAF was associated with 
late onset stroke only if accompanied by a low cardiac output syndrome (3.9 versus 1.9%) [66]. 
Besides, POAF development is associated with a prolonged length of hospitalization [2, 25, 54]. 
The POAF is associated with an additional 2–4 days hospital stay after CABG surgery with an 
additional cost [54]. However, this effect seems to be less prominent with current cardiac surgical 
care [67]. Additionally, POAF may result in hemodynamic compromise [68], ventricular dysrhyth-
mias [2], and iatrogenic complications associated with therapeutic interventions [53]. POAF may 
result in increased in-hospital and long-term mortality in a subset of patients [3, 60]. In a retrospec-
tive study of 6475 patients undergoing CABG at a single institution: 994 patients (15%) developed 
POAF. Higher in-hospital (7.4 versus 3.4%) and 4-year mortality (26 versus 13%) was noted in 
POAF patients but also with more comorbidities (i.e., older age, hypertension, and left ventricular 
hypertrophy) [60].
3.1.5. POAF management
The management of POAF should include the strategy for prevention and treatment of POAF 
when it develops. PAOF management starts with the optimization of medical comorbidities, 
if possible (e.g., hypoxia), and the correction of underlying electrolyte disturbances (e.g., 
potassium and magnesium abnormalities) [53]. POAF is treated similarly to AF in nonsurgical 
patients by rhythm control via pharmacological or electrical approach or heart rate control, 
and appropriate antithrombotic therapy.
3.1.5.1. Rhythm control versus heart rate control
In the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) trial, the 
rate control versus rhythm control in nonsurgical patients with AF was studied and found 
that the use of rhythm control had no survival advantage, and it was associated with more 
frequent hospitalizations and adverse drug effects [69]. However, some studies involving 
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patients with AF after cardiac surgery have suggested that rhythm control may offer advan-
tages over rate control. This is still controversial and the evidence is inconclusive [11, 70–72].
Treatment strategies of POAF aim to reduce symptoms, limit adverse hemodynamic effects, 
decrease the length of hospital stay, prevent readmissions, and improve survival [73]. The 
rhythm control strategy has the advantage of a rapid conversion to sinus rhythm, which 
restores atrial activity, functional capacity, and might reduce thromboembolic. The rate con-
trol strategy has the advantage of avoiding the potential adverse effects of antiarrhythmic 
drugs and complications associated with cardioversion [73]. In a recent trial, there was no dif-
ference in hospital admissions during a 60-day follow-up, with randomizing POAF patients 
to either rhythm control therapy with amiodarone or rate control [73]. As a result, the main 
aim of rhythm control therapy in POAF patients should be to improve AF-related symptoms. 
In asymptomatic patients and those with acceptable symptoms, rate control or deferred car-
dioversion preceded by anticoagulation is a reasonable approach [73].
In the following paragraph, rate control and rhythm control options will be discussed briefly.
(A) Rate control strategy: the rate control may be achieved by using beta-blockers, nondihy-
dropyridine calcium channel blockers, digoxin, or a combination of these medications. Beta-
blocker agents are the drug of choice, particularly for ischemic heart disease patients, because 
of the increased adrenergic stress in the postoperative period [53, 73, 74]. However, beta-block-
ers might be poorly tolerated or relatively contraindicated in patients with known bronchial 
asthma or bronchospastic lung diseases, active congestive heart failure, or AV conduction 
block [53]. The nondihydropyridine calcium channel blocker agents represent an alternative 
AV nodal blocking agent. Digoxin is less effective when the adrenergic tone is as high as in the 
postoperative period, but it may be used in patients with congestive heart failure. Amiodarone 
is another agent that can be used as it has been reported to be effective in controlling heart rate. 
Also, intravenous amiodarone administration has been associated with improved hemody-
namic status [75, 76]. For further information about drugs used in AF rate control see Table 1.
(B) Rhythm control: the rhythm control could be archived by using a direct current cardio-
version (electrical cardioversion) or antiarrhythmic drugs (pharmacological cardioversion). 
Electrical cardioversion is indicated on an urgent basis in hemodynamically unstable patients, 
acute heart failure, or myocardial ischemia. Also, it may be used electively to restore sinus 
rhythm when a pharmacologic attempt has failed to resume a sinus rhythm [53]. Rhythm con-
trol with antiarrhythmic medications is preferred in symptomatic patients despite rate control 
trial, or when the control of ventricular response is hard to achieve. Amiodarone [77–79] or ver-
nakalant [79, 80] have been efficient in converting POAF to sinus rhythm. Other antiarrhyth-
mic medications that may be used include procainamide [80], ibutilide [81], and sotalol [82]. 
With ibutilide use, electrolyte imbalance should be corrected to avoid polymorphic ventricular 
tachycardia [82]. For further information about drugs used in AF rhythm control see Table 2.
3.1.5.2. Anticoagulation
POAF is associated with poor short- and long-term outcomes, including high rates of early and 
late stroke, and late mortality as mentioned earlier. However, the indication and timing of anti-
coagulation in POAF patients should take into consideration the risk of postoperative bleeding. 
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Drug Route of admintration and doses Side effects sects Remarks
Beta-blockers
Atenolol Oral 25–100 mg QD Bradycardia, hypotension, 
fatigue, depression, negative 
inotropy, bronchospasm, AVB
Decrease dose if  
CrCl <35
Bisoprolol Oral 2.5–10 mg QD As above Good choice for  
HF patients
Carvedilol Oral 3.125–25 mg BID As above Good choice for  
HF patients
Esmolol I.V. 500 mcg/kg bolus over 1 min,  
then 50–300 mcg/kg/min
As above Only IV
Higher rate  
of hypotension
Metoprolol 
tartrate
IV 2.5–5.0 mg bolus over 2 min;  
up to 3 doses Oral 25–100 mg BID
As above
Metoprolol XL 
(succinate)
Oral 50–400 mg QD As above Good choice for  
HF patients
Nadolol Oral 10 (usual initial adult dose  
40 mg)–240 mg QD
As above Dosage adjustments 
based on CrCl
Propranolol IV 1 mg over 1 min, up to 3 doses  
at 2-min intervals
Oral 10–40 mg up to 160–320 mg/day 
divided in BID to QID doses
80–160 to 320 mg QD (ER)
As above
Calcium channel blockers
Diltiazem IV 0.25 mg/kg bolus over 5 min followed by 
0.05–0.15 mg/kg/h continuous infusion
Oral 30 mg TID/QID up to 480 mg/day
120–360 to 480 mg Q D (ER)
Bradycardia, hypotension, 
ankle swelling, exacerbation 
of HF, AVB
Do not use in HF
Drug interaction via 
CYP3A4 including 
digoxin and warfarin
Verapamil IV 5–10 mg (0.075–0.15 mg/kg) over bolus 
at least 2 min; may give an additional 10 mg 
(0.15 mg/kg) after 30 min if no response, 
then 0.005 mg/kg/min infusion
Oral 80–120 mg TID up to 480 mg/day
180–480 mg QD or 240 BID (ER)
Bradycardia, AVB, 
hypotension, constipation, 
exacerbation of HF
As diltiazem
Others
Digoxin IV 0.25 mg IV with repeat dosing to a 
maximum of 1.5 mg over 24 h
Oral 0.125–0.25 mg QD
Bradycardia, AVB, nausea, 
vomiting, visual disturbance
Narrow therapeutic 
window
Adjust for renal failure
Drug interactions via 
p-glycoprotein
Amiodarone IV 150 mg over 10 min, followed by 1 mg/
min continuous IV infusion for 6 h, then 0.5 
mg/min continuous infusion for 18 h
Oral 400–800 mg/day PO in divided doses 
for 2–4 weeks to a total load of up to 10 g, 
then 100–200 mg QD
Bradycardia, hypotension, 
AV block, QTc prolongation, 
phlebitis on chronic use: 
Ocular, pulmonary, hepatic, 
hematological, neurological 
complications
Monitor thyroid, liver 
and lung functions
AVB, atrioventricular block; CrCl, creatinine clearance; BID, twice daily; h, hour; ER, extended release; HF, heart failure; 
IV, intravenous; mg milligram; min, minute; QD, once daily; QID, 4 times a day; QTc, correct QT interval; TID, 3 times 
a day.
Table 1. Medications commonly used for atrial fibrillation rate control with its dosage and common possible side effects.
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Drug Usual doses Side effects sects Additional information
Vaughan Williams class IA
Disopyramide Oral
IR 100–200 mg q 6 h
ER 200–400 mg q 12 h
HF
Prolonged QT interval
Prostatism
Glaucoma
Metabolized by CYP3A4: caution with 
inhibitors (e.g., verapamil, diltiazem, 
ketoconazole, macrolide antibiotics, 
protease inhibitors, grapefruit juice) and 
inducers (e.g., phenytoin, phenobarbital, 
rifampin)
Avoid other QT interval prolonging drugs
Procainamide IV 15–17 mg/kg infused 
at a rate of 20–30 mg/min 
or alternatively100 mg IV 
every 5 min, max. 1 g
MD 1–4 mg/min
HF
Prolonged QT interval
May cause hypotension, 
myopathies, blood 
dyscrasias, and SLE-like 
syndrome
Drug of choice for WPW with AF
Avoid other QT interval prolonging drugs
Adjust for renal failure
Quinidine Oral
IR 200–300 mg q 6–8 h up to 
600 mg q 6 h
ER 324 mg–648 mg q 8–12 h
Prolonged QT interval
Diarrhea
Bradycardia, AV block, 
bundle-branch block, 
digitalis toxicity
Inhibits CYP2D6: ⇧ concentrations of 
metoprolol, tricyclic antidepressants, 
antipsychotics; ⇩ efficacy of codeine
Inhibits P-glycoprotein:⇧ digoxin 
concentration
Vaughan Williams class IC
Flecainide IV 1.5–3 mg/kg over 
10-20 min
Oral
LD 200 (wt < 70 kg)–300 mg 
(wt > 70 kg),
MD 50–200 mg BID max. 
400 mg/day
Sinus or AV node 
dysfunction
HF
CAD
Atrial flutter
Brugada syndrome
Renal or liver disease
May cause blurred vision
Metabolized by CYP2D6 (inhibitors 
include quinidine, fluoxetine, tricyclics; 
also genetically absent in 7–10% of 
population) and renal excretion (dual 
impairment can ⇧⇧ plasma concentration)
Decrease dose if CrCl < 35
Propafenone IV 1.5–2 mg/kg over 
10–20 min
Oral
IR: 150–300 mg q 8 h
ER: 225–425 mg q 12 h
(Oral LD 450 mg (wt < 70 
kg)–600 mg (wt > 70 kg), 
MD 450–900 mg/d divided 
into q 8 h (IR), or 12 h (ER))
Sinus or AV node 
dysfunction or 
Infranodal conduction 
disease
HF
CAD
Atrial flutter
Brugada syndrome
Liver disease
Asthma may cause 
dysgeusia
Metabolized by CYP2D6 (inhibitors 
include quinidine, fluoxetine, tricyclics; 
also genetically absent in 7–10% of 
population)—poor metabolizers have 
⇧beta blockade
Inhibits P-glycoprotein: ⇧digoxin 
concentration
Inhibits CYP2C9: ⇧warfarin concentration 
(⇧INR 25%)
Decrease dose in hepatic failure
Vaughan Williams class III
Amiodarone IV LD 150 mg over 10 min; 
followed by 1 mg/min for 6 
h; then 0.5 mg/min for 18 h or 
change to oral dosing; after 
24 h, consider decreasing 
dose to 0.25 mg/min
Oral 400–600 mg daily 
in divided doses for 2–4 
wk; maintenance typically 
100–200 mg QD
Sinus or AV node 
dysfunction
Infranodal conduction 
disease
Lung disease
Prolonged QT interval
Inhibits most CYPs to cause drug 
interaction: ⇧concentrations of warfarin 
(⇧INR between 0–200%), statins, many 
other drugs
Inhibits P-glycoprotein: ⇧digoxin 
concentration
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Oral anticoagulation at discharge has been associated with a reduced long-term mortality in 
patients with POAF [83] but without evidence from controlled trials [75]. POAF that persists 
for longer than 48 h should be anticoagulated with warfarin or nonvitamin K antagonist oral 
anticoagulants (NOACs). The NOACs are available for the treatment of nonvalvular AF. NOACs 
have been found to be as efficacious or even superior to warfarin in the prevention of stroke in 
nonvalvular AF patients with high risk of thromboembolism, with similar to lower rates of major 
bleeding, and also lower rates of intracranial hemorrhage [84].
Drug Usual doses Side effects sects Additional information
Dronedarone Oral 400 mg BID Bradycardia
HF
Liver disease
Thyriod disease
pulmonary fibrosis
Prolonged QT interval
Metabolized by CYP3A: caution with 
inhibitors (e.g., verapamil, diltiazem, 
ketoconazole, macrolide antibiotics, 
protease inhibitors, grapefruit juice) and 
inducers (e.g., phenytoin, phenobarbital, 
rifampin) Inhibits CYP3A, CYP2D6, 
P-glycoprotein: ⇧concentrations of some 
statins, digoxin, beta blockers, sirolimus, 
tacrolimus
Avoid in long-standing persistent or 
permanent AF and HF
Dofetilide Oral 125–500 mcg BID if 
CrCl >60, 250 mcg if CrCl 
40–60, 125 mcg if CrCl 
20–40
Decrease MD if QTc 
increased by >15% of >500 
ms 2–3 h after dose or 
consider discontinuing it
Prolonged QT interval 
and torsades de pointes
Renal disease
Hypokalemia 
hypomagnesaemia
AV block, bradycardia, 
sick sinus syndrome
Adjust dose for renal function, body size, 
and age (avoid if CrCl < 20)
Drug interactions via CYP3A4: CI to use 
with verapamil, cimetidine, ketoconazole, 
trimethoprim, prochlorperazine, HCTZ, 
and megestrol
Discontinue amiodarone at least 3 m 
before initiation
Avoid other QT interval prolonging drugs
Ibutilide IV 1 mg over 10 min; may 
repeat 1 mg
once if necessary (if weight 
<60 kg, use 0.01 mg/kg)
Prolonged QT interval 
and torsade de pointes 
hypotension
CAD
HF
Mointor K and mg level
Sotalol Oral 40–160 mg q12 h
IV 75–150 mg QD or BID 
over 5 h (only if patient 
cannot take oral)
Prolonged QT interval
Sinus or AV nodal 
dysfunction
HF
Renal excretion: CI if Cr Cl <40 decrease 
dose if CrCl 40–60
Risk of torsade de pointes ( do not initiate 
sotalol therapy if the baseline QTc is longer 
than 450 ms. If the QT interval prolongs 
to 500 ms or greater, the dose must be 
reduced, the duration of the infusion 
prolonged or the drug discontinued) 
Avoid other QT interval prolonging drugs 
correct hypokalemia/hypomagnesemia
ACC AF [74]; JACC [53]. AF, atrial fibrillation; AV, atrioventricular; BID, twice daily; CAD, coronary artery disease; CI, 
contraindicated; CrCl, creatinine clearance; ER, extended release; h, hour; HCTZ, hydrochlorothiazide; HF, heart failure; 
IL, immediate release; IV, intravenous; LD, loading dose; INR, international normalized ratio; MD, maintenance dose; min, 
minute; max, maximum; SLE, systemic lupus erythematosus; Q, every; QD, once daily; wt, weight. http://www.pdr.net/
Table 2. Medications commonly used for atrial fibrillation Rythm Control with its dosage and major pharmacokinetic 
and drug interactions.
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3.1.6. Prevention of POAF
Beta-blockers are effective in reducing POAF and SVTs. Propranolol uses reduced POAF inci-
dence from 31.7% in the control group to 16.3% in the treatment group [85]. In the majority 
of beta-blocker studies, it is administered postoperatively [86]. Amiodarone reduced the inci-
dence of POAF and hospital stay compared to beta-blocker therapy in several meta-analyses 
[86–89]. Prophylactic administration of sotalol may be considered for patients at risk of devel-
oping AF after cardiac surgery [76, 90, 91]. Also, administration of colchicine postoperatively 
may reduce POAF [75, 92]. Statin use preoperatively did not prevent POAF in a prospective 
controlled trial [93], despite that initial reports from meta-analyses were encouraging [94–96].
Other therapies for the prevention of POAF have been studied in small trials, but have not 
demonstrated clear beneficial effects [76]. These include angiotensin converting enzyme 
inhibitors (ACEIs) [97], magnesium [85, 98, 99], n-3 polyunsaturated fatty acids [100–108], 
corticosteroids [109–111], and posterior pericardiectomy [112]. Conflicting results have also 
been reported for acetylcysteine [113], and sodium nitroprusside [114].
Nonpharmacologic therapy with atrial pacing has been tested in various studies [7]. One meta-anal-
ysis showed a significant reduction in POAF with atrial pacing (OR 0.57, 95% CI 0.38–0.84) [67], and 
most [115–117] but not all [118, 119] published studies showed benefit with this therapy. Besides, 
there are conflicting findings as to the relative value of the different types of atrial pacing [115, 116].
3.2. Postoperative atrial flutter (POAFL)
Unlike POAF, POAFL after CABG is not well studied. In a single-center study with 80 con-
secutive patients who underwent CABG with no previous history of AFL, 16 patients (20%) 
had documented POAFL. Ten of these patients showed temporary AFLs that were curable 
without radiofrequency catheter ablation (RFCA), and 37.5% of the patients with POAFL (i.e., 
7.5% of the patients after CABG) showed sustained or repeated AFL with subjective symp-
toms [120]. In another study that looked at ATs late after open heart surgery, it was found that 
cavotricuspid isthmus (CTI)-dependent AFL was the most common. Atypical AFL becomes 
progressively more widespread with more extensive atriotomy [121]. AFL and ATs that devel-
oped late after cardiac surgery are believed to be due to scars created by incisions applied 
to the right and/or left atrium either for establishing extracorporeal circulation or access to 
intracardiac structures (coronary sinus, interatrial or interventricular septum, atrioventricular 
valves, etc.) [122]. The scars created by these incisions play a significant role in the develop-
ment of ATs, months or years after surgery [123, 124].
AFL in the early postoperative period is managed as POAF with rate control or rhythm con-
trol and anticoagulation based on arrhythmia duration and patient risk factors. On long-term 
catheter ablation of AFL is an effective, safe, and potentially curative procedure.
3.3. Supraventricular tachycardia (SVT)
3.3.1. Epidemiology
Sinus tachycardia (ST) represents an appropriate autonomic response to a physiological 
stress. The upper limit of normal rate for sinus tachycardia is calculated from the formula 
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(220 bpm minus age) [125]. Inappropriate ST may be seen in some patients, especially with 
young age, but it is rare and should be considered a diagnosis of exclusion [125]. The term 
‘SVT’ refers to paroxysmal tachyarrhythmias that require atrial or AV nodal tissue, or both, 
for their initiation and maintenance [126]. It is typical of a sudden or paroxysmal onset and 
includes AV nodal reentrant tachycardias (AVNRT), AV reentrant tachycardias (AVRT), and 
atrial tachycardias. The overall incidence of perioperative arrhythmias in noncardiac surgery 
varies from 16 to 62% with intermittent ECG monitoring and up to 89% with continuous 
Holter monitoring [127]. It is more likely to be supraventricular than ventricular in origin 
[127]. In small study, the incidence of persistent SVT in noncardiac surgery patients was 2% 
during surgery and 6% in the postoperative period [128].
3.3.2. Diagnosis
12-lead ECG and rhythm strips during tachycardia are diagnostic and may give an impres-
sion about the most likely diagnosis. Although ST is usually easy to diagnose on 12-lead ECG, 
the presence of first-degree AV block, which is not uncommon after cardiac surgery, may give 
ECG appearance that mimics SVT due to P wave merge with T wave (P wave hidden within 
T wave). ECG features of ATs including SVTs are shown in Table 3.
3.3.3. Clinical course
ATs occur most frequently 2–3 days postsurgery and are likely related to sympathetic stimu-
lation associated with an inflammatory response [129]. Patients with known SVT may have 
an exacerbation of their tachycardia in the perioperative period. However, SVT may be diag-
nosed for the first time in the perioperative period [2, 7, 130, 131]. SVT is often associated with 
a high sympathetic tone, but other precipitants may contribute to its occurrence. The clinical 
symptoms, time of onset, and natural course of ATs are identical in patients with cardiac, 
thoracic, or other surgery.
3.3.4. Prognosis
The prognosis of perioperative SVTs is good, but it may be associated with increased hospital 
stay [128].
3.3.5. Management
The SVT management, in general, depends on the hemodynamic status of the patient. If 
the patient with SVT is hemodynamically unstable, synchronized cardioversion is recom-
mended for acute termination of the tachycardia when vagal maneuvers or adenosine is 
ineffective or not feasible [132]. Before initiating specific drug therapy for acute SVT in 
hemodynamically stable patients, it is important to assess and correct possible precipitat-
ing factors such as respiratory failure or electrolyte imbalance. SVT may respond to vagal 
maneuver if the patient can do it. Adenosine might be used if there is no contraindication. 
SVT also responds to rate control drugs such as beta-blockers (e.g., esmolol, metoprolol, 
bisoprolol) or nondihydropyridine calcium channel antagonists (e.g., diltiazem, verapamil). 
Intravenous (IV) digoxin, IV amiodarone, adenosine, IV or oral beta-blockers, diltiazem, and 
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verapamil are potentially harmful in acute treatment in patients with pre-excited AF (AF in 
patients with Wolff-Parkinson-White (WPW) syndrome) [133]. Of note, atrial tachycardia 
unifocal or multifocal usually respond to rate control drugs but are not amenable to direct 
current cardioversion. Cardiac electrophysiology study with catheter ablation is an effective 
long-term management for recurrent SVT.
4. Postoperative ventricular tachyarrhythmias (POVTAs)
The postoperative ventricular tachyarrhythmias (POVTAs) range from isolated PVC to VT or 
ventricular fibrillation (VF).
4.1. Premature ventricular complexes (PVCs)
4.1.1. Epidemiology
Isolated PVCs including nonsustained ventricular tachycardia (NSVT) are seen in about 50% 
of patients during and after cardiac surgery [134]. PVCs can be related to electrolyte or other 
metabolic imbalances [7].
4.1.2. Diagnosis
PVCs may be seen on continuous telemetric monitoring and 12-lead ECG, however, careful 
evaluation of the ECG tracing is needed to be distinguished from atrial ectopy with aberrant 
ventricular conduction [7].
4.1.3. Clinical course
Patients with postoperative PVCs may be asymptomatic or may have palpitations with a 
skipped beat, or dizziness. It is rarely associated with hemodynamic instability.
4.1.4. Prognosis
Patients with isolated and noncomplicated PVCs postoperatively do not exhibit increased 
risk of malignant VAs [135, 136]. On the contrary, frequent PVCs (>30 per hour) may reduce 
ventricular function and therefore have an adverse impact on the short-term outcome. There 
was no significant difference in mortality in patients with versus patients without frequent 
postoperative PVCs and NSVT (8 versus 5%), at an average follow-up of 3 years, in a study 
including 185 postoperative patients [137]. However, in another study of 126 patients with 
postoperative PVCs, it was shown that patients with left ventricular ejection fraction (LVEF) 
of <40% had a 75% mortality rate and 33% incidence of sudden death at an average follow-
up of 15 months, whereas none of the patients with preserved left ventricular function had 
sudden death [135]. Thus, PVCs are not related to mortality with good LV function, and long-
term outcome after cardiac surgery seems to be closely related to the left ventricular function.
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4.1.5. Management
Correction of any reversible cause of ventricular arrhythmias should be performed. Hemo 
dynamically stable and asymptomatic PVCs do not usually need treatment with antiarrhyth-
mic therapy on short or long-term. Lidocaine has been used with a successful result in reducing 
hemodynamically significant or symptomatic PVCs, but without improving mortality. Empirical 
use of class I antiarrhythmic drugs for suppression of frequent and/or complex PVCs had no ben-
eficial effects on mortality rate and may be harmful as shown in several studies in another setting 
[138, 139]. Additionally, overdrive pacing, using either atrial or atrioventricular sequential pac-
ing, has been used without significant results [138, 139]. Patients with asymptomatic NSVT after 
cardiac surgery and preserved LVEF generally have a favorable long-term prognosis and do not 
require invasive workup with an electrophysiology study. The use of implantable cardioverter 
defibrillators (ICDs) has shown no benefits in improving prognosis in this population [140].
4.2. Ventricular tachyarrhythmias
4.2.1. Epidemiology
Sustained VT and VF rarely occur after cardiac surgery with an incidence of 0.4–1.7% in most 
of the studies [138, 141], but an incidence of 3.1% has been reported [142]. Furthermore, it is 
life threatening and affects outcome [134, 143].
4.2.2. Pathophysiology and risk factors
Pathophysiology of POAs, in general, was disused in item 2. Coronary artery disease (CAD) 
leads to a broad spectrum of changes and may trigger arrhythmia mechanisms via enhanced 
automaticity, triggered activity, and reentry. While myocardial infarction (MI) related scar 
constitutes the clinical model of reentry [144], focal activation due to abnormal automaticity 
is the primary mechanism involved in the VT during acute ischemia [145]. Early and delayed 
after depolarization result from focal discharge by calcium overload and triggered activity is 
another likely mechanism of VT initiation in ischemia, but this needs to be proven experimen-
tally thus far [146, 147]. Acute ischemia activates the adenosine triphosphate-sensitive potas-
sium (K-ATP) channels, causing an increase in extracellular potassium along with acidosis 
and hypoxia in the cardiac muscle. As a result of the minor increases in extracellular potas-
sium depolarize the myocardiocyte’s resting membrane potential, which can increase tissue 
excitability in early phases of ischemia [145]. The mechanism underlying the VT associated 
with healed or healing MI is reentry in more than 95% of cases [144].
Complex ventricular arrhythmias (VAs) are associated with multiple risk factors [7]. Based 
on clinical studies, the conditions associated with VAs after cardiac surgery may include: 
increased age, female gender, presence of unstable angina, congestive cardiac failure, hemo-
dynamic instability, preoperative use of inotropes, preoperative use of IABP, emergency sur-
gery, electrolyte disturbances, hypoxia, hypovolemia, myocardial ischemia/infarction, acute 
graft closure, reperfusion after cessation of CPB, and inotropes antiarrhythmic drugs use, 
on-pump surgery, and PVD [134, 135, 141, 143, 148].
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Heart rate (bpm) Regularity Onset Atrial activity Response to 
adenosine
Rhythm strip
AF A: 350-500
V: 100- 220
Irregular Sudden No discrete P-waves Transient slowing 
of ventricular rate
AFL A: 250-350
V: 150 
(slower or faster 
depends on AV 
conduction)
Regular
( irregular 
with 
variable AV 
conduction) 
Sudden Flutter waves “saw-
tooth” pattern) 
Transient slowing 
of ventricular rate
ST 220-age Regular Gradual Normal P-waves Transient slowing
AT 150-250 Regular Sudden Abnormal P-waves 
morphology
-Transient 
slowing of 
ventricular rate 
-May terminate 
tachycardia in 
70% of the cases
AVNRT 150-250 Regular Sudden No obvious P-waves 
as P- wave is in or 
just after QRS
(Pseudo r’ in V1 or 
S wave in inferior 
leads)
Termination of 
tachycardia
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Heart rate (bpm) Regularity Onset Atrial activity Response to 
adenosine
Rhythm strip
AVRT 
(WPW)
150-250 Regular Sudden ORT: P-waves 
may be buried in 
QRS complex, or 
retrograde P wave 
may be seen at the 
end of the QRS 
complex or in the 
early part of the ST 
segment
Termination of 
tachycardia
ART: P wave 
normal with 
short PR and 
delta wave (wide 
QRS complexes 
due to abnormal 
ventricular 
depolarization via 
accessory pathway)
Termination of 
tachycardia
AF: no P-wave, 
irregular rhythm, 
and wide QRS 
complex
Should not be 
used
Table 3. Differential diagnosis of atrial tachyarrhythmias.
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4.2.3. Diagnosis
In addition to a clinical history and a physical exam, the general evaluation of a patient with 
CAD and suspected or documented VAs includes performing a 12-lead ECG and an echo-
cardiogram. Telemetry monitoring with careful evaluation of VAs initiation and termination 
is very helpful. Based on ECG criteria, wide complex tachycardias (WCT) may be either 
ventricular or SVT with aberrancy. However, in patients with structural heart disease like 
prior infarction, the diagnosis is mostly VT. If feasible, a 12-lead ECG and atrial electrograms 
through temporary epicardial wires placed at the time of cardiac surgery should be obtained. 
The presence of AV dissociation strongly suggests VT [138]. Although the ECG diagnosis of a 
WCT is challenging, it is important to remember that VT is the cause in at least 80% of cases 
[149].
4.2.4. Clinical course
Clinical presentation of patients post cardiac surgery with VTs is variable. The hemodynamic state 
of these patients depends mainly on the rate of the tachyarrhythmia and the left ventricular func-
tion. Therefore, some patients may be asymptomatic. Other patients with VT may complain of 
palpitations, dyspnea, or chest discomfort as their main symptoms. VTs may present with syn-
cope and sudden cardiac death as a result of hemodynamic compromise. Incessant VT, even if it 
is hemodynamically stable, can lead to hemodynamic deterioration and heart failure [150, 151].
4.2.5. Prognosis
The prognosis is correlated with the type of arrhythmia and the type and degree of structural 
heart disease [7]. As mentioned earlier, PVCs and NSVT generally have no impact on the 
outcome. However, patients with sustained VAs have poorer short- and long-term prognosis.
POVAs predicts higher in-hospital mortality (21.7–31.5%) compared with (1.4–2.9%) in con-
trol [134, 143, 148]. In one study, POVAs was associated with increased long-term mortality 
over a mean follow-up of 3.5 years. Patients with POVAs had a high risk of death in the 
POVAs group during the first 6 postsurgical months (6-month survival of POVAs 59.8 versus 
93.8% for POVAs free group). This difference in survival persisted over time [148].
4.2.6. Management of POVAs
Asymptomatic PVCs and hemodynamically stable short runs of NSVT do not need spe-
cific intervention, and the correction of any reversible cause of VAs is generally sufficient. 
Postoperative sustained VAs treatment follows the ICD indications used in other clinical set-
tings [150, 152]. However, the postoperative patients require close attention to the identifi-
cation and treatment of reversible causes of arrhythmia like electrolyte or other metabolic 
disturbances, myocardial ischemia, or mechanical complications of surgery [7]. Sustained 
VAs should be promptly cardioverted either by drugs infusion or electrically based on hemo-
dynamic stability. Hemodynamically stable sustained VTs may be initially treated with anti-
arrhythmic drugs infusion.
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4.2.6.1. Pharmacological treatment
It includes antiarrhythmic medication use and standard medical therapy. The most com-
monly used antiarrhythmic agents include:
- Amiodarone: IV amiodarone is frequently used as a first-line treatment for VAs as it is bet-
ter tolerated in patients with low ejection fraction than the other antiarrhythmic drugs. The 
recommended starting dose of Cordarone I.V. is 1000 mg over the first 24 h of therapy. It is 
usually delivered by bolus infusion of 150 mg over 10–15 min, followed by 1 mg/min for 6 h, 
then 0.5 mg/min infusion for 18 h. The alternative dose would be 300 mg over 1 h then infu-
sion at 50 mg/h. Additional 150 mg blouses may be given but frequent boluses during the first 
24 h should be limited due to the risk of hepatic toxicity [153].
- Lidocaine: it is generally a good choice if ischemia is suspected. Lidocaine is administered 
as a bolus of 0.75–1.5 mg/kg, followed by an IV infusion of 1–4 mg/min (the maximal dose is 
3 mg/kg/h). In elderly patient and patients with congestive heart failure or hepatic dysfunc-
tion, the lidocaine dose should be reduced [153].
- Procainamide: it is often a second line drug, and it is given as loading dose of 15–18 mg/kg 
administered as a slow infusion over 25–30 min or 100 mg/dose. The infusion rate should not 
exceed 50 mg/min. The loading dose may be repeated every 5 min as needed to a total dose of 1 
g. However, it should be stopped if hypotension occurs, or QRS complex widens by 50% of its 
original width. This is followed by a maintenance dose of 1–4 mg/min by continuous infusion. 
The procainamide maintenance infusion should be reduced by 1/3 in patients with moderate 
renal or cardiac impairment and by 2/3 in patients with severe renal or cardiac impairment [153].
Standard medical therapy includes beta-blockers, and ACEIs drugs have been demonstrated 
to improve long-term survival particularly in patients with left ventricular dysfunction.
4.2.6.2. Nonpharmacological management
- Overdrive pacing: in patients with slower VTs who have ventricular epicardial wires, over-
drive pacing may be performed. Electrical cardioversion/defibrillation should be easily avail-
able because of the possibility of acceleration of the VT or degeneration to VF [154].
- Electrical cardioversion/defibrillation: in patients with cardiac arrest, basic life support (BLS) 
and advanced cardiovascular life support (ACLS) should be followed. Electrical  defibrillation 
should be performed for VF, pulseless VT, and hemodynamically unstable VT. Electrical car-
dioversion may be used for stable sustained VT as the first choice or for those who do not 
respond to antiarrhythmic medications. The recommended energy with current biphasic defi-
brillators ranges from 150 to 200 Joules. Sedation with short-acting agents should precede 
cardioversion in awake patients [154].
- Emergency mechanical support: in postoperative patients who are not responding to stan-
dard resuscitation maneuvers, initiation of emergency CPB in the intensive care unit may be 
considered. In one study, CPB use in a postoperative cardiac arrest was associated with a 56% 
long-term survival rate with a 22% incidence of soft tissue infections and no mediastinitis [154].
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- Implantable cardioverter-defibrillator (ICD) therapy:
In the absence of a reversible cause of sustained VT or cardiac arrest after CABG, long-term 
management may include electrophysiology study and eventually an ICD implantation. 
Patients with NSVT, prior MI, and left ventricular dysfunction (LVEF <40%) may be considered 
for electrophysiology testing and implantation of an ICD if a sustained ventricular arrhythmia 
is induced [152, 155]. Multicenter automatic defibrillator implantation trial (MADIT) study 
[152] excluded subjects within 2 months after CABG and 3 months after percutaneous trans-
luminal coronary angioplasty (PTCA), and MADIT-II study [156] excluded subjects within 3 
months after revascularization. Conversely, early revascularization was permitted in MUSTT 
(Multicenter Unsustained Tachycardia Trial) study [155], which enrolled subjects at least 4 days 
after revascularization, and sudden cardiac death in heart failure trial (SCD-HeFT) study [157] 
made no specific exclusion on the timing of revascularization. However, in SCD-HeFT, the 
median time from CABG to enrollment was 3.1 years, and from PCI to enrollment was 2.3 years. 
Therefore, ICD implantation within 90 days of coronary revascularization for patients who 
otherwise meet ICD implant criteria for primary prevention of sudden cardiac death (SCD) is 
not addressed in the published device-based therapy guidelines. Revascularization has signifi-
cant time-dependent benefits. In fact, MADIT-II study showed that the efficacy of ICD therapy 
in patients with ischemic left ventricular dysfunction is time dependent, with a significant 
life-saving benefit in patients receiving device implantation more than 6 months after coronary 
revascularization (CR). The lack of ICD benefit early after CR may be related to a relatively 
small risk of SCD during this period [158]. Although, sudden cardiac arrest (SCA) has a higher 
incidence in patients with reduced LVEF in the months after acute MI and/or following revas-
cularization [159, 160]. The two randomized controlled trials, defibrillator in acute myocardial 
infarction (DINAMIT) and immediate risk stratification improves survival (IRIS), showed that 
early ICD implantation does not reduce mortality [161, 162]. In both of those trials, there was 
a reduction in arrhythmic death, which was counteracted by a concomitant increase in death 
due to other causes [163]. Similarly, the coronary artery bypass graft (CABG)-patch trial [164] 
examined ICD implantation at the time of elective CABG surgery showed a small decrease 
in arrhythmic death, but no benefit for overall mortality in patients with preoperative LVEF 
≤35%. However, one should keep in mind that the epicardial ICDs tested in this trial differed 
significantly from the current transvenous endocardial ICD systems. A retrospective study 
evaluating ICD implantation within 3 months of cardiac surgery suggested the benefit of ICD 
implantation for  secondary prevention. In this study, 164 patients were with ICD implanta-
tion within 3 months of cardiac surgery; 93 of these patients had an ICD for sustained pre 
or postoperative VT or VF requiring resuscitation. During the mean follow-up of 49 months; 
the primary endpoint was total mortality (TM) and/or appropriate ICD therapy (ICD-T), and 
secondary endpoints are the TM and ICD-T, and individual end points of TM and ICD-T were 
observed in 52 (56%), 35 (38%), and 28 (30%) patients, respectively, with 55% of TM, and 23% 
of ICD-T occurring within 2 years of implant [165].
Overall, ICD for primary prevention of SCD can be useful in patients who are within 90 days of 
revascularization and who are not within 40 days of an acute MI if:
- they are previously qualified for primary prevention of SCD or
- revascularization is unlikely to result in an improvement in LVEF to level >35% [166].
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ICD for secondary prevention (i.e., in patients resuscitated from cardiac arrest due to VT/VF) is 
recommended for patients within 90 days of revascularization who have:
- previously satisfied criteria for ICD implantation if they have abnormal left ventricular func-
tion or
- SCD is unlikely related to myocardial ischemia/injury and have normal left ventricular func-
tion [166].
ICD implantation can be useful in patients who are within 90 days of revascularization if SCD 
was not related to acute myocardial ischemia/injury and who were subsequently found to 
have coronary artery disease that is revascularized with normal left ventricular function, or 
SCD was not related to acute myocardial ischemia/injury and who were subsequently found 
to have coronary artery disease that is revascularized with normal left ventricular function 
[166]. ICD is not recommended in patients within 90 days of revascularization who were resus-
citated from cardiac arrest due to VT that was related to acute MI/injury, with normal left 
ventricular function, and who undergo complete coronary revascularization [166]. ICD with 
appropriately selected pacing capabilities is recommended in patients within 90 days of revas-
cularization who require nonelective permanent pacing, who would also meet primary pre-
vention criteria for implantation of an ICD, and in whom recovery of left ventricular function 
is uncertain or not expected [166].
An alternative approach for primary prevention of SCD in patients with ischemic cardiomy-
opathy and low LVEF undergoing revascularization would be the use the wearable cardio-
verter-defibrillator vest during the 3 months waiting period after revascularization until LVEF 
is reassessed and design made about permanent ICD implantation [163].
- Ventricular tachycardia ablation:
There are no studies of VT ablation in POVAs situation. In patients with extensive struc-
tural abnormalities, especially those with prior MI, multiple morphologies of VT might 
develop. Therefore, VT ablation does not eliminate the need for ICD and/or antiarrhyth-
mic therapy. VT episodes might occur in up 0–60% of patients who have received an ICD 
for secondary prevention and in 2.5–12% of patients with ICD implanted for primary 
prevention [167]. Because antiarrhythmic drugs do not eliminate the risk of VAs, VT cath-
eter ablation may be needed to reduce the frequency of VT episodes, especially patients 
with incessant VT or frequent ICD therapy [149]. Ablation is usually indicated in cases 
of recurrent, monomorphic VT arising from a specific substrate that can be targeted by 
mapping techniques.
5. Postoperative bradyarrhythmias (POBAs)
5.1. Epidemiology
Bradyarrhythmias (BAs) are common after cardiac surgery, but it mostly consists of tran-
sient episodes of low ventricular heart rate. The conduction defects post cardiac surgery 
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include sinus node dysfunction, partial and complete bundle branch blocks, and various 
degrees of atrioventricular (AV) block. The right bundle branch block (RBBB) was the most 
frequently noted abnormality [168]. Bradyarrhythmias may decrease cardiac output in 
patients with relatively fixed stroke volumes. The risk of developing conduction distur-
bances after CABG or valvular surgery leading to permanent pacemaker (PPM) implanta-
tion is about 0.4–1.1% of patients after isolated CABG and 3–6% after heart valve operations 
[169–171]. It seems that in the current surgical era that the incidence of postoperative PPM 
implantation has decreased due to improvements in surgical techniques, technological 
innovations and enhanced understanding of the mechanisms of injury [172]. However, 
some studies have shown an increased incidence of PPM implantation after cardiac surgery 
after the year 2000 [173].
5.2. Pathophysiology and risk factors
Conduction disorders after cardiac surgery are explained by one of the following two mecha-
nisms: (1) direct trauma to the conduction system in operative procedures in proximity to the 
sinoatrial or AV nodes or the His bundle; or (2) ischemic injury to the conduction system due 
to extensive coronary artery disease might compromise myocardial protection during intra-
operative cardioplegic arrest [174].
The risk factors for POBAs may be classified as preoperative, operative, and postoperative 
factors. Preoperative risk factors include age >75 years, the use of rate lowering cardiac medi-
cations (e.g., beta-blockers, calcium channel blockers, digoxin, and antiarrhythmic drugs), the 
presence of conduction system disease preoperatively, right bundle branch block (RBBB) or 
left bundle branch block (LBBB), first-degree AV block or left anterior fascicular block (LAFB) 
[169–171, 175–178].
Operative risk factors include myocardial ischemia, inadequate cardiac protection during sur-
gery, and direct surgical injury to conduction system, prolonged CPB time and cross-clamp 
time, and reoperation [171, 172, 174, 179, 180].
Postoperative risk factors include postoperative conduction disturbances and high-grade AV 
block [174, 175, 181].
5.3. Clinical course and management
Temporary electrical pacing may be required in symptomatic bradycardias. It is common 
practice nowadays to place temporary epicardial atrial and ventricular pacing wires placed 
at the time of surgery to facilitate temporary pacing when needed. In some cases, as men-
tioned above, the conduction defect does not revert, and permanent pacing may be necessary. 
Chronotropic medications, such as theophylline or aminophylline, have been used for sinus 
bradycardia after transplantation to improve SSS [182] or high-grade AVB [183] and may 
decrease the need for permanent pacing but its long-term effect is not encouraging.
The challenge with POBAs is often to determine when to implant the PPM as the sinus node 
function or AV conduction may recover in some patients. Recovery of conduction system is 
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common with long-term follow-up. Only 30–40% of patients with a permanent pacemaker 
due to sinus node disease remain pacemaker dependent. However, the rate of recovery is less 
in patients with postoperative AVB, as 65–100% of patients with complete heart block, remain 
pacemaker dependent. Currently, the usual practice is to implant a PPM if postoperative 
symptomatic complete AVB or severe sinus node dysfunction persists longer than 5–7 days 
[184]. PPM implantation may be considered earlier if the underlying intrinsic rhythm is absent 
or temporary pacing leads fail.
6. Conclusion
Arrhythmias are common after CABG. Although tachyarrhythmias are frequent, they are usu-
ally transient and have a benign course. POAF represents the most frequently observed ATs. 
VAs are less common but have an adverse impact on the short and long-term outcome. POTAs 
management includes optimization of the patient’s condition, controlling patient’s risk fac-
tors, and careful attention to hemodynamic changes during surgery with using appropriate 
anesthesia. Postoperatively, it is important to correct reversible arrhythmia predisposing fac-
tors, followed by specific therapy based on the arrhythmia type and its hemodynamic effect.
On the other hand, bradyarrhythmias are also frequently observed after cardiac surgery. 
However, most of the conduction disturbances are transient and recovered spontaneously. 
PPM implantation may be required in patients with persistent symptomatic bradycardia due 
to sick sinus syndrome or second degree type 2, third degree, or high-grade AV block.
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